Patent ID: 9468667
Filing Date: 2016-10-18
CPC Classification: A61B,A61F,A61K,C12N,Y10T

Claim Text:
1. A method of delivering at least one recombinant gene product selected from growth hormone, interferon β, insulin, PDGF-BB, interleukin 1 receptor agonist (IL-1Ra), peptide YY3-36, interleukin 10 (IL-10), and G-CSF to a subject comprising implanting into or underneath the skin at least one genetically modified dermal micro-organ that expresses and secretes said at least one recombinant gene product or at least a portion of said at least one recombinant gene product, a. wherein said at least one recombinant gene product comprises growth hormone, interferon β, insulin, PDGF-BB, interleukin 1 receptor agonist (IL-1Ra), peptide YY3-36, interleukin 10 (IL-10) or G-CSF; b. wherein said genetically modified dermal micro-organ is autologous with said subject; c. wherein said dermal micro-organ is an explant of living tissue consisting essentially of a plurality of dermal components and lacking a complete epidermal layer that substantially maintains the micro-architecture and three-dimensional structure of the dermal tissue from which it is obtained, and having dimensions allowing passive diffusion of nutrients and gases to cells of said dermal micro-organ and diffusion of cellular waste out of said cells; d. wherein at least some of the cells of said genetically modified dermal micro-organ express and secrete at least a portion of said at least one recombinant gene product; and e. wherein said implanting of said at least one genetically modified dermal micro-organ delivers growth hormone, interferon β, insulin, PDGF-BB, interleukin 1 receptor agonist (IL-1Ra), peptide YY3-36, interleukin 10 (IL-10) or G-CSF, or at least a portion of thereof, to said subject.